Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allegro's DME Drug Could Over-Throw Off-Label Avastin, Says CMO

Executive Summary

Phase IIb data prove Allegro Ophthalmics' injectable diabetic macular edema treatment, Luminate, is non-inferior to marketed VEGF treatments, but the drug still faces entry into a competitive market with numerous approved options and rivalry from cheaper alternatives used off-label for DME patients.



Related Companies